Please assess the completion status of the following clinical trial:

Trial Title: Fatty Acid Supplementation in Children With ASD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2-6 years old~* ASD diagnosis at Nationwide Children's Hospital within the prior 6 months~* ADOS-2 score in autism (severe) range~* English is primary language~Exclusion Criteria:~* Fatty acid supplementation in the past 6 months~* Consumes fatty fish more than 3 times per week~* Still breastfeeding or formula feeding~* Quadriparesis~* Deafness~* Blindness~* Seizure disorder diagnosis~* Autoimmune disorder including Type 1 Diabetes, Fragile X, Rett, Angleman Syndromes, Tuberous Schlerosis~* Feeding problems precluding consumption of the supplement~* Ingredient allergy (canola, fish, or borage seed)~* Planned surgeries scheduled within the time frame of trial participation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- LCPUFA Oil Supplement, Low Dose (Type: EXPERIMENTAL): 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
- LCPUFA Oil Supplement, Medium Dose (Type: EXPERIMENTAL): 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
- LCPUFA Oil Supplement, High Dose (Type: EXPERIMENTAL): 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
- Canola Oil (Type: PLACEBO_COMPARATOR): Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).